Paricalcitol NEW
| Price | $147 | $597 | $852 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Paricalcitol | CAS No.: 131918-61-1 |
| Purity: 99.5% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Paricalcitol |
| Description | Paricalcitol is a vitamin D receptor agonist. It is used for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. |
| Animal Research | After TAC or sham surgery, a subset of the mice is treated with paricalcitol which activates the VDR, at a final dose of 300 ng/kg/day. Paricalcitol is dissolved in a 95% propylene glycol and 5% ethyl alcohol solution. Mice were intraperitoneally injected with paricalcitol (or vehicle only) three times per week on Monday, Wednesday, and Friday for five consecutive weeks. An established anti-hypertrophic and anti-fibrotic treatment, namely the angiotensin II receptor blocker (ARB) losartan is also included. Previous experiments have shown it is feasible and efficacious to dissolve losartan in the drinking water at a concentration of 30 mg/kg/day; mice are treated for five consecutive weeks. So, in total eight groups are studied. Sham (n=10), TAC (n=10), Sham + losartan (Sham-los, n=10), TAC + losartan (TAC-los, n=10), Sham + paricalcitol (Sham-pari, n=10), TAC + paricalcitol (TAC-pari, n=10), Sham + paricalcitol + losartan (Sham-combi, n=10) and TAC + paricalcitol + losartan (TAC-combi, n=10) [2]. |
| In vitro | Paricalcitol (30 nM; HP + PC) produces a significant reduction in calcification relative to the observed in cells in HP medium. Paricalcitol causes a reduction in the levels of nuclear β-catenin to a level similar to that observed in control cells [1]. |
| In vivo | Paricalcitol, administered at a dosage of 300 ng/kg/day, markedly reduces Tau levels and prevents left ventricular (LV) dysfunction in mice. Furthermore, this treatment significantly lowers the mRNA expression of atrial natriuretic peptide (ANP), fibronectin, and collagen III in mice subjected to transverse aortic constriction (TAC-pari) [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : Insoluble Ethanol : 12 mg/mL (38.8 mM), Sonication is recommended. DMSO : 95 mg/mL (228.02 mM), Sonication is recommended. |
| Keywords | Vitamin D receptor | Vitamin D | Inhibitor | VD/VDR | Paricalcitol | inhibit |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP3Y
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2024-11-08 | |
| $0.00/1Kg |
VIP1Y
|
airuikechemical co., ltd.
|
2024-04-03 | |
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-08-11 | ||
| $1.00/1g |
ANHUI WITOP BIOTECH CO., LTD
|
2021-03-22 | ||
| $12.00/1KG |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2021-02-07 | |
| $0.01/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-07 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY